Matthew Steven Davids, M.D.
This page shows the publications co-authored by Matthew Davids and Charles Herbaux.
BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia. Blood. 2021 Jun 24; 137(25):3495-3506.
Venetoclax: R-CHOP rocket booster? Blood. 2019 05 02; 133(18):1922-1924.
Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia. Haematologica. 2021 08 01; 106(8):2251-2256.
Serine-70 phosphorylated Bcl-2 prevents oxidative stress-induced DNA damage by modulating the mitochondrial redox metabolism. Nucleic Acids Res. 2020 12 16; 48(22):12727-12745.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.